Evidence map›Paper›PMID 30777075›Full record

SynthesisLipids in health and disease2019

Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials.

Chengfeng Qiu, Xiang Zhao, Lang She, Zhihua Shi, Ziwei Deng, Liming Tan, Xiaojun Tu, Shilong Jiang, Bin Tang

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Lipids in health and disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 3 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Chengfeng QiuDepartement of Evidence-base Medcine and Clinical center, The First People's Hospital of Huaihua of University of South China, Huaihua, 418000, People's Republic of China.
Xiang ZhaoDepartment of General Practice, The First People's Hospital of Huaihua of University of South China, Huaihua, 418000, People's Republic of China.
Lang SheDepartment of Pharmacology, The First People's Hospital of Huaihua of University of South China, Huaihua, 418000, People's Republic of China.
Zhihua ShiDepartment of Pharmacology, The First People's Hospital of Huaihua of University of South China, Huaihua, 418000, People's Republic of China.
Ziwei DengDepartment of Pharmacology, The First People's Hospital of Huaihua of University of South China, Huaihua, 418000, People's Republic of China.
Liming TanDepartment of Pharmacology, The Second People's Hospital of Huaihua City, Huaihua, 418000, People's Republic of China.
Xiaojun TuDepartement of Evidence-base Medcine and Clinical center, The First People's Hospital of Huaihua of University of South China, Huaihua, 418000, People's Republic of China.
Shilong JiangDepartment of Clinical Pharmaccology, Xiangya Hospital Central South University, Changsha, 410008, People's Republic of China.
Bin TangDepartement of Evidence-base Medcine and Clinical center, The First People's Hospital of Huaihua of University of South China, Huaihua, 418000, People's Republic of China. huaihuatangbin@163.com.ORCID http://orcid.org/0000-0002-5194-6336
Huaian First People’s Hospital · CNCentral South University · CNHuaihua University · CNXuzhou Medical College · CN

Funding

Natural Science Foundation of Hunan Province 2017JJ3250
6 · The paper itself

Abstract

backgroundBaricitinib, an oral-administrated selective inhibitor of the JAK1 and JAK2, is recently approved for rheumatoid arthritis (RA) treatment. With the aim to provide some insights on the clinical safety, the current study mainly focused on the effect of baricitinib on low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels and cardiovascular risk.

methodsThe net change scores [least squares mean (LSM) and mean change] of LDL-C and HDL-C levels from baseline with the comparison of baricitinib versus placebo were pooled, respectively. Risk rations (RR) of major cardiovascular events (MACEs) and differences of cardiovascular risk scores at the end of treatment across groups were compared.

resultsSix trials with randomized 3552 patients were finally included in summary analysis. Results showed that baricitinib significantly increased LDL-C levels, the net mean change was 13.15 mg/dl with 95% CI 8.89~17.42 (I

conclusionThis study confirmed that baricitinib induced a stable dose-response increase in LDL-C and HDL-C levels. Since the causality association between altered lipids and cardiovascular risk was not identified yet, this issue cannot be completely dismissed. Future research is needed to fully dissect the implications of these lipid changes.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAzetidinesCardiovascular DiseasesCholesterol, HDLCholesterol, LDLDose-Response Relationship, DrugDrug Administration ScheduleGene ExpressionHumansJanus Kinase 1Janus Kinase 2Protein Kinase InhibitorsPurinesPyrazolesRandomized Controlled Trials as TopicAntirheumatic AgentsAzetidinesbaricitinibCholesterol, HDLCholesterol, LDLJAK1 protein, humanJAK2 protein, humanJanus Kinase 1Janus Kinase 2Protein Kinase InhibitorsPurinesPyrazolesSulfonamidesBaricitinibCardiovascular riskHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolRheumatoid arthritis

Identifiers

PMID30777075
PMCPMC6380020
OpenAlexW2923178573

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.